Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial - Wikidata - awgldk - TriplyDB

Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial

Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial

http://www.wikidata.org/entity/Q33796997

about

Circulating serologic and molecular biomarkers in malignant melanoma Transcriptome profiling of whole blood cells identifies PLEK2 and C1QB in human melanoma Melanoma immunotherapy using mature DCs expressing the constitutive proteasome.Circulating tumor cells in melanoma patients Genetic factors in metastatic progression of cutaneous melanoma: the future role of circulating melanoma cells in prognosis and management.Aberrant fatty acid-binding protein-7 gene expression in cutaneous malignant melanoma.Serial monitoring of circulating tumor cells predicts outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma.Association of circulating tumor cells with serum tumor-related methylated DNA in peripheral blood of melanoma patients Estrogen receptor-alpha methylation predicts melanoma progression Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients.PAX2 regulates ADAM10 expression and mediates anchorage-independent cell growth of melanoma cells Molecular upstaging based on paraffin-embedded sentinel lymph nodes: ten-year follow-up confirms prognostic utility in melanoma patients Assessment of prognostic circulating tumor cells in a phase III trial of adjuvant immunotherapy after complete resection of stage IV melanoma.Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trial.Activation of Toll-like receptors 2, 3, and 4 on human melanoma cells induces inflammatory factors.Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma.Capture and On-chip analysis of Melanoma Cells Using Tunable Surface Shear forces Circulating tumor cells in melanoma: a review of the literature and description of a novel technique.Molecular markers of circulating melanoma cells.Prognostic molecular biomarkers for cutaneous malignant melanoma High expression of TRF2, SOX10, and CD10 in circulating tumor microemboli detected in metastatic melanoma patients. A potential impact for the assessment of disease aggressiveness Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma.Functional RET G691S polymorphism in cutaneous malignant melanoma.Activation of CCR9/CCL25 in cutaneous melanoma mediates preferential metastasis to the small intestine.Liquid Biopsies for Assessing Metastatic Melanoma Progression.Circulating tumor cells in uveal melanoma.Circulating melanoma cells in the diagnosis and monitoring of melanoma: an appraisal of clinical potential.Neoadjuvant treatment of melanoma: case reports and review.The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.Liquid biopsy utility for the surveillance of cutaneous malignant melanoma patients Transcriptional repression of IFNβ1 by ATF2 confers melanoma resistance to therapy.mRNA expression and BRAF mutation in circulating melanoma cells isolated from peripheral blood with high molecular weight melanoma-associated antigen-specific monoclonal antibody beads.Cytokeratin 20 positive cells in blood of colorectal cancer patients as an unfavorable prognostic marker.Prognostic relevance of occult nodal micrometastases and circulating tumor cells in colorectal cancer in a prospective multicenter trial.Neoadjuvant systemic therapy for regionally advanced melanoma.

P2860

Q27020946-DB12C645-8FF4-44A5-A5F6-5B69F269CE15 Q28743603-79F740B7-5305-49F9-813D-22272DF642DC Q30541002-11AD8105-AEBD-4CC5-88C0-FF51ABD8404F Q31075758-BA5967DE-05FB-4347-8698-99487E649FAA Q33350614-B1848FEE-3476-4923-9775-8B8E730482EB Q33754941-862B26A1-2D69-49C4-B086-8D2AAB6BA70E Q33794086-8290C9EE-CA41-46BE-9AE5-7AF6438F44F7 Q33797039-1631FCE2-48D1-4B87-94EA-6553CFEF8BAD Q33797076-309F1B50-19E5-4E16-AC6C-CE427ACC2500 Q33797088-5EED01A5-C3FF-4FB1-8EE1-B6FB81D6DBE7 Q34005367-2503369C-451C-4964-8BD2-329E6869AD5D Q34614180-DBF96B9D-F98F-4FA5-992B-C2398777952E Q35874030-B1C83B28-435D-4237-8E03-6224DA445AD4 Q36339707-FE940E3A-BFBE-49BA-9398-7176BA00E802 Q36345961-F6436EF3-1FA4-4C74-A96E-84D4ADF73F17 Q36452245-B9DEA656-4A91-41D0-9DFF-A2CDA1AA8996 Q36507245-73BCD4F3-06A5-4E24-93E1-A7F054D472FE Q36514253-6BEF8974-6D16-4E6F-BD17-B36977661B2B Q36764220-8E6DBD4C-A3E4-45BF-A610-1698D989853D Q36905877-A60A22DD-D3C6-46B3-AA8C-BF8F6E4FD68A Q37045507-198601BA-AF9E-4C72-9EF2-589DD10BFCE8 Q37192910-3058D25F-D050-4166-9E40-61B78064C1DA Q37334690-F8949F40-07BE-4B59-A2CC-BBC6C0E5FD4A Q37385045-C571DA86-AE47-4E93-9C08-5BC97BD8637B Q37667080-7A5477CE-9B67-4CFF-BA14-B28816B7723F Q37822739-20D1FC7C-F824-4A26-93EB-A8E0345683DE Q38168103-F2F2AF32-CC96-4970-A01E-2E65C498C9DA Q38185477-C1F55BAC-4ED0-4F1C-8472-724241DFA846 Q38620826-859AF4D4-81D9-4078-A44C-61A553044FB0 Q38700529-0AB029CC-813C-4B4D-ADA4-5639B92B6DEA Q38904811-59DC7A54-F06B-4051-A418-FF29524D0521 Q39881143-5C62E118-3BD8-477A-BA94-8AEC5318560E Q40769679-6F19EF8D-3A8B-4522-BD18-0FA823A37AE5 Q43179836-43672CAB-0311-4469-AEF8-DA16E78E1109 Q47329770-FF286BA4-71EE-4208-B311-3D7E4F0A4075

P2860

Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trial

http://www.wikidata.org/entity/Q33796997

description

2005 nî lūn-bûn

@nan

2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2005 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2005年の論文

@ja

2005年論文

@yue

2005年論文

@zh-hant

2005年論文

@zh-hk

2005年論文

@zh-mo

2005年論文

@zh-tw

2005年论文

@wuu

name

Serial monitoring of circulati ...... diction in a multicenter trial

@ast

Serial monitoring of circulati ...... diction in a multicenter trial

@en

type

label

Serial monitoring of circulati ...... diction in a multicenter trial

@ast

Serial monitoring of circulati ...... diction in a multicenter trial

@en

prefLabel

Serial monitoring of circulati ...... diction in a multicenter trial

@ast

Serial monitoring of circulati ...... diction in a multicenter trial

@en

P1433

Q33796997-9539229C-6AEC-450F-826D-4EAA125CA54F

P1476

Q33796997-362F2B76-3294-4F3A-A61F-8D9226C9836E

P2093

Q33796997-1FB4D4CE-9A2D-416B-8D19-A6BCF4B71522

Q33796997-4050C26E-2AFE-44EC-84C4-DC7956F9550A

Q33796997-5690A2A9-1835-4444-949F-200770A33852

Q33796997-594BAEB7-674F-4C83-B080-5E57E37672A2

Q33796997-6AC65367-4C10-4A0F-90CA-F393A009DDF6

Q33796997-95D547A4-2D57-45FE-B4BA-8CCF5E88193D

Q33796997-9B63ABC2-1784-497A-9294-B4E78685BDF7

Q33796997-A1DA1107-9305-452B-B007-ADBA548609E9

Q33796997-C564142F-2359-448B-9731-5F1D25DE38E7

Q33796997-E4146249-E1E2-4AD2-8D20-078270300297

P2860

Q33796997-15D6099C-F353-4CCB-B01C-498ABC3A7F9F

Q33796997-1EB372EC-CBC5-4654-AFA7-3F6E36005AF4

Q33796997-273BD826-A743-4FAB-9F11-B998DCE78D19

Q33796997-5AB5562E-96E1-458D-A141-D98163335C14

Q33796997-5F9845E9-D526-4622-8C8F-FDDFADD09488

Q33796997-64E84F69-314E-425F-8E0C-C806FF102F8E

Q33796997-74E6D472-AEBC-4178-A2DB-BBDB33DFD6A4

Q33796997-763E01EE-F649-4ECB-BFA7-3191C6BEE75A

Q33796997-7A90723F-19F2-45A9-ABF5-514CBE26DF89

Q33796997-89740AB6-2886-4EC2-A1A3-05444BE460FB

P304

Q33796997-70C467BA-5163-4542-A267-CD085989AD7C

P31

Q33796997-9213960B-02FE-445F-986B-829FBACCC627

P356

Q33796997-E7614BFE-9C21-4D26-BB8B-A8FBE8076A6F

P407

Q33796997-900C0085-747B-4909-9A07-929885D766ED

P433

Q33796997-9FE5E443-8E49-4FE8-B21C-62C3C7F513DA

P478

Q33796997-19A95605-0D9F-4DA1-9483-625E1A31A841

P50

Q33796997-D61C55ED-7B4A-4925-8C6F-92AD630E27D0

P577

Q33796997-4D483328-0FD0-46CF-9AF2-B95621516696

P698

Q33796997-F76431B9-63CD-4737-9969-9CA903023173

P921

Q33796997-25342B0C-FDB6-4725-AFD5-04C72AACD0A7

P932

Q33796997-910CF8DC-B01E-40C1-A25C-4708581E0544

P356

JCO.2005.02.0958

P1433

Journal of Clinical Oncology

P1476

Serial monitoring of circulati ...... diction in a multicenter trial

@en

P2093

He-Jing Wang

http://www.w3.org/2001/XMLSchema#string

Hiroya Takeuchi

http://www.w3.org/2001/XMLSchema#string

Karl Lewis

http://www.w3.org/2001/XMLSchema#string

Kazuo Koyanagi

http://www.w3.org/2001/XMLSchema#string

Naoyuki Umetani

http://www.w3.org/2001/XMLSchema#string

Rene Gonzalez

http://www.w3.org/2001/XMLSchema#string

Robert M Elashoff

http://www.w3.org/2001/XMLSchema#string

Steven J O'Day

http://www.w3.org/2001/XMLSchema#string

Thomas T Amatruda

http://www.w3.org/2001/XMLSchema#string

William A Robinson

http://www.w3.org/2001/XMLSchema#string

P2860

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

PAX3 is expressed in human melanomas and contributes to tumor cell survival

Circulating tumor cells, disease progression, and survival in metastatic breast cancer

Detection and clinical importance of micrometastatic disease.

Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients

Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients

Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma.

The clinical utility of multimarker RT-PCR in the detection of occult metastasis in patients with melanoma.

Sequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trial.

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanoma.

P304

8057-8064

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.02.0958

http://www.w3.org/2001/XMLSchema#string

P407

P433

31

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

P577

2005-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

16258104

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

2856446

http://www.w3.org/2001/XMLSchema#string